Chemotherapy Induced Nausea and Vomiting Drugs Market Trends, Size, Competitive Analysis and Forecast 2022-2028

The global chemotherapy-induced nausea and vomiting drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The term chemotherapy-induced nausea and vomiting includes emesis and nausea, which can involve a loss of appetite and result in the decreased oral intake of fluids and calories. Therefore, for the management of such conditions, the demand for chemotherapy-induced nausea and vomiting drugs is likely to grow in the near future. Further, the growing geriatric population along with the rising prevalence of cancer are acting as the pivotal factors responsible for the increased demand for these drugs.

The global chemotherapy-induced nausea and vomiting drugs market is also driven by extensive R&D along with new FDA approvals. For instance, in April 2021, Caplin Steriles has been granted final approval from the US FDA for its abbreviated new drug application (ANDA) prochlorperazine edisylate injection USP, 10 mg/2 mL (5 mg/mL) vials. Prochlorperazine edisylate injection is a drug that is indicated for the control of severe nausea and vomiting.

To Request a Sample of our Report on Chemotherapy Induced Nausea and Vomiting Drugs Market: https://www.omrglobal.com/request-sample/chemotherapy-induced-nausea-and-vomiting-drugs-market

Some major key players in the market include Novartis International AG, F. Hoffman La-Roche AG, and Merck & Co., Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2021, Heron Therapeutics, Inc. announced the submission of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion. HTX-019 injectable emulsion is intended to be used for the prevention of postoperative nausea and vomiting (PONV) in adults.

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2022-2028

Segment Covered-

· By Type

· By Therapy

· By Drug Type

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: Novartis International AG, F. Hoffman La-Roche AG, and Merck & Co., Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Chemotherapy Induced Nausea and Vomiting Drugs Market is Available @ https://www.omrglobal.com/industry-reports/chemotherapy-induced-nausea-and-vomiting-drugs-market

Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Report by Segment

By Type

· Acute Emesis

· Delayed Emesis

· Anticipatory Emesis

· Refractory Emesis

By Therapy

· Nk-1 Receptor Antagonist

· Serotonin Receptor Antagonist

· Others

By Drug Type

· Branded

· Generics

Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.